Roche Xenical Patient Retention Program Is Key To Sales Growth
Executive Summary
Roche has set up a Xenical patient retention program in the U.S. in a continuing effort to improve the obesity drug's sales record.
You may also be interested in...
Xenical Diabetes sNDA Withdrawn; FDA, Roche Disagree On Wording
Roche is contemplating how to pursue a type 2 diabetes indication for Xenical after withdrawing a supplemental NDA for the claim
Xenical Diabetes sNDA Withdrawn; FDA, Roche Disagree On Wording
Roche is contemplating how to pursue a type 2 diabetes indication for Xenical after withdrawing a supplemental NDA for the claim
Roche Sees Pegasys Approval Delay Until 2002, But With Broader Indication
Roche's "current expectation" for the pegylated interferon product Pegasys is that it will be approved in the first half of 2002, with an indication covering both monotherapy and combination use.